Principal Lecturer/Reader in the Research Institute for Health and Social Change at Manchester Metropolitan University
Pro to the question "Should Marijuana Be a Medical Option?"
"A priori cannabis use was recorded at index admission for 112 participants in the Manchester first-episode psychosis cohort. 69 of the 100 surviving (mainly schizophrenia) patients were followed up 10–12 years later and assessed on a battery of clinical, behavioural and neurocognitive measures. Individuals who had not used cannabis before the first episode of illness were generally indistinguishable from cannabis users at follow-up, except that the latter group evidenced a marked ‘sparing' of neurocognitive functions...
"[C]annabis users had better cognitive functioning than patients without cannabis use in several domains including design memory, verbal fluency, object assembly, block design, picture completion, picture arrangement, and face recognition memory."
"Cannabis Use Prior to First Onset Psychosis Predicts Spared Neurocognition at 10 Year Follow-up," Schizophrenia Research, Oct. 21, 2004
Experts PhD's and JD's (lawyers) with significant post-doctoral involvement in medical marijuana issues; judges who have presided over medical marijuana cases. [Note: Experts definition varies by site.]
Involvement and Affiliations:
Principal Lecturer/Reader, Research Institute for Health and Social Change, Manchester Metropolitan University
Consultant Neuropsychologist, University of Manchester
Member, British Neuroscience Association
Member, International Brain Research Organisation
Member, Schizophrenia Association of Great Britain
Member, Rethink (formally National Schizophrenia Fellowship)
Member, Schizophrenia Interest Group (University of Manchester)